Nuclear medicine imaging methods as novel tools in the assessment of pulmonary drug disposition

References

• Cooper AE, Ferguson D, Grime K. Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab. 2012;13(4):457–473.
   PubMed Web of Science ®Google Scholar
• Anderson S, Atkins P, Bäckman P, et al. Inhaled medicines: past, present, and future. Pharmacol Rev. 2022;74(1): 48–118.
   PubMed Web of Science ®Google Scholar
• de Kruijf W, Ehrhardt C. Inhalation delivery of complex drugs-the next steps. Curr Opin Pharmacol. 2017;36:52–57.
   PubMed Web of Science ®Google Scholar
• Weibel ER, Gomez DM. Architecture of the human lung. Use of quantitative methods establishes fundamental relations between size and number of lung structures. Science. 1962;137(3530):577–585.
   PubMedGoogle Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
   PubMed Web of Science ®Google Scholar
• Bäckman P, Cabal A, Clark A, et al. iBCS: 2. mechanistic modeling of pulmonary availability of inhaled drugs versus critical product attributes. Mol Pharm. 2022;19(7): 2040–2047.
   PubMedGoogle Scholar
• Forbes B, Asgharian B, Dailey LA, et al. Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev. 2011;63(1–2):69–87.
   PubMed Web of Science ®Google Scholar
• Scheuch G, Bennett W, Borgstrom L, et al. Deposition, imaging, and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 2): S39–57.
   PubMedGoogle Scholar
• Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des. 2000;6(16):1631–1651.
   PubMed Web of Science ®Google Scholar
• Conway J. Lung imaging - two dimensional gamma scintigraphy, SPECT, CT and PET. Adv Drug Deliv Rev. 2012;64(4):357–368.
   PubMed Web of Science ®Google Scholar
• Newman SP, Pitcairn GR, Hirst PH, et al. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev. 2003;55(7):851–867.
   PubMed Web of Science ®Google Scholar
• Walker PS, Conway JH, Fleming JS, et al. Pulmonary clearance rate of two chemically different forms of inhaled pertechnetate. J Aerosol Med. 2001;14(2):209–215.
   PubMedGoogle Scholar
• Corcoran TE, Niven R, Verret W, et al. Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. J Aerosol Med Pulm Drug Deliv. 2014;27(3):178–184.
   PubMed Web of Science ®Google Scholar
• Sangwan S, Agosti JM, Bauer LA, et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aerosol Med. 2001;14(2):185–195.
   PubMedGoogle Scholar
• Häussermann S, Winnips C, Edelman J, et al. Lung deposition of alpha1-proteinase inhibitor (human) (A1-PI[H]) inhalation solution using two inhalation modes of the I-neb adaptive aerosol delivery (AAD) system in healthy subjects and subjects with cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2016;29(3):242–250.
   PubMed Web of Science ®Google Scholar
• Köhler D, Fleischer W, Matthys H. New method for easy labeling of beta-2-agonists in the metered dose inhaler with technetium 99m. Respiration. 1988;53(2):65–73.
   PubMed Web of Science ®Google Scholar
• Lee Z, Berridge MS, Nelson AD, et al. The effect of scatter and attenuation on aerosol deposition as determined by gamma scintigraphy. J Aerosol Med. 2001;14(2):167–183.
   PubMedGoogle Scholar
• Depreter F, Burniat A, Blocklet D, et al. Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. Eur J Pharm Biopharm. 2012;80(1):4–13.
   PubMed Web of Science ®Google Scholar
• Brand P, Meyer T, Weuthen T, et al. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47(10):1335–1341.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Bailey DL. Positron emission tomography (PET) for assessing aerosol deposition of orally inhaled drug products. J Aerosol Med Pulm Drug Deliv. 2012;25(1):S52–71.
   PubMedGoogle Scholar
• Borgström L, Newman S, Weisz A, et al. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci. 1992;81(8):753–755.
   PubMed Web of Science ®Google Scholar
• Newman SP, Moren F, Trofast E, et al. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J. 1989;2(3):247–252.
   PubMed Web of Science ®Google Scholar
• Fuller HD, Dolovich MB, Turpie FH, et al. Efficiency of bronchodilator aerosol delivery to the lungs from the metered dose inhaler in mechanically ventilated patients. A study comparing four different actuator devices. Chest. 1994;105(1):214–218.
   PubMed Web of Science ®Google Scholar
• Häussermann S, Acerbi D, Brand P, et al. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med. 2007;20(3):331–341.
   PubMedGoogle Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137–148.
   PubMed Web of Science ®Google Scholar
• Tal A, Golan H, Grauer N, et al. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr. 1996;128(4):479–484.
   PubMed Web of Science ®Google Scholar
• Verbanck S, Biddiscombe MF, Usmani OS. Inhaled aerosol dose distribution between proximal bronchi and lung periphery. Eur J Pharm Biopharm. 2020;152:18–22.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504.
   PubMed Web of Science ®Google Scholar
• Warren S, Taylor G, Smith J, et al. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J Aerosol Med. 2002;15(1):15–25.
   PubMedGoogle Scholar
• Saari SM, Vidgren MT, Turjanmaa VM, et al. No impairment of peripheral deposition in novel asthmatics treated with an MDI corticosteroid with spacer. Respir Med. 2003;97(2):152–158.
   PubMed Web of Science ®Google Scholar
• Newman SP, Sutton DJ, Segarra R, et al. Lung deposition of Aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78(3):322–328.
   PubMed Web of Science ®Google Scholar
• Usmani O, Roche N, Wahab E, et al. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir Res. 2021;22(1):261.
   PubMed Web of Science ®Google Scholar
• Kappeler D, Sommerer K, Kietzig C, et al. Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler. Respir Med. 2018;138:107–114.
   PubMed Web of Science ®Google Scholar
• Galindo-Filho VC, Alcoforado L, Rattes C, et al. A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: a randomized controlled trial with radiolabeled aerosols. Respir Med. 2019;153:60–67.
   PubMed Web of Science ®Google Scholar
• Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763–770.
   PubMedGoogle Scholar
• Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv. 2009;22(2):131–138.
   PubMed Web of Science ®Google Scholar
• Coates AL, Green M, Leung K, et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol. 2008;43(8):753–759.
   PubMed Web of Science ®Google Scholar
• Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere(R) insulin inhalation powder administration. Pharm Res. 2011;28(9):2157–2164.
   PubMed Web of Science ®Google Scholar
• Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100(3):375–384.
   PubMed Web of Science ®Google Scholar
• Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med. 2006;19(2):117–126.
   PubMedGoogle Scholar
• Mason NS, Mathis CA. Positron emission tomography radiochemistry. Neuroimaging Clin N Am. 2003;13(4):671–687.
   PubMed Web of Science ®Google Scholar
• Li Z, Conti PS. Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev. 2010;62(11):1031–1051.
   PubMed Web of Science ®Google Scholar
• Miller PW, Long NJ, Vilar R, et al. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Angew Chem Int Ed Engl. 2008;47(47):8998–9033.
   PubMed Web of Science ®Google Scholar
• Jacobson O, Kiesewetter DO, Chen X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26(1):1–18.
   PubMed Web of Science ®Google Scholar
• Wolf W. Imaging can be much more than pretty pictures. Pharm Res. 1995;12(12):1821–1822.
   PubMed Web of Science ®Google Scholar
• Fischman AJ, Alpert NM, Rubin RH. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet. 2002;41(8):581–602.
   PubMed Web of Science ®Google Scholar
• Burt T, Young G, Lee W, et al. Phase 0/microdosing approaches: time for mainstream application in drug development? Nat Rev Drug Discov. 2020;19(11):801–818.
   PubMed Web of Science ®Google Scholar
• Van der Veldt AAM, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012;21(1):82–91.
   PubMed Web of Science ®Google Scholar
• Sundelin EI, Gormsen LC, Jensen JB, et al. Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther. 2017;102(5):841–848.
   PubMed Web of Science ®Google Scholar
• Ordonez AA, Wang H, Magombedze G, et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat Med. 2020;26(4):529–534.
   PubMed Web of Science ®Google Scholar
• Jucaite A, Stenkrona P, Cselenyi Z, et al. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study. Neuro Oncol. 2021;23(4):687–696.
   PubMed Web of Science ®Google Scholar
• Brown NF, Williams M, Arkenau HT, et al. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098. Neuro Oncol. 2018;20(12):1634–1642.
   PubMed Web of Science ®Google Scholar
• Heuveling DA, de Bree R, Vugts DJ, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013;54(3):397–401.
   PubMed Web of Science ®Google Scholar
• Thorneloe KS, Sepp A, Zhang S, et al. The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans. EJNMMI Res. 2019;9(1):45.
   PubMedGoogle Scholar
• Wollmer P, Pride NB, Rhodes CG, et al. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet. 1982;2(8312):1361–1364.
   PubMed Web of Science ®Google Scholar
• Bajc M, Neilly JB, Miniati M, et al. EANM guidelines for ventilation/perfusion scintigraphy: part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging. 2009;36(8):1356–1370.
   PubMed Web of Science ®Google Scholar
• Bäckström E, Lundqvist A, Boger E, et al. Development of a novel lung slice methodology for profiling of inhaled compounds. J Pharm Sci. 2016;105(2):838–845.
   PubMed Web of Science ®Google Scholar
• Luptakova D, Vallianatou T, Nilsson A, et al. Neuropharmacokinetic visualization of regional and subregional unbound antipsychotic drug transport across the blood-brain barrier. Mol Psychiatry. 2021;26(12):7732–7745.
   PubMed Web of Science ®Google Scholar
• Berridge MS, Lee Z, Heald DL. Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. J Nucl Med. 2000;41(10):1603–1611.
   PubMed Web of Science ®Google Scholar
• Berridge MS, Cassidy EH, Bordeaux KG. Preparation of [C-11] triamcinolone acetonide. Appl Radiat Isot. 1994;45(1):91–95.
   Web of Science ®Google Scholar
• Lee Z, Heald D, Berridge MS. Comparison of PET and gamma scintigraphy: validation studies. J Aerosol Med. 1999;12:134.
   PubMedGoogle Scholar
• Berridge MS, Heald DL. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography. J Clin Pharmacol. 1999;39(S1):25S–29S.
   PubMedGoogle Scholar
• Berridge MS, Heald DL, Muswick GJ, et al. Biodistribution and kinetics of nasal carbon-11-triamcinolone acetonide. J Nucl Med. 1998;39(11):1972–1977.
   PubMed Web of Science ®Google Scholar
• Spiro SG, Singh CA, Tolfree SE, et al. Direct labelling of ipratropium bromide aerosol and its deposition pattern in normal subjects and patients with chronic bronchitis. Thorax. 1984;39(6):432–435.
   PubMed Web of Science ®Google Scholar
• Virgolini I, Kurtaran A, Leimer M, et al. Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med. 1997;38(9):1475–1481.
   PubMed Web of Science ®Google Scholar
• Issa F, Kassiou M, Chan HK, et al. Synthesis and radiolabelling of ipratropium and tiotropium for use as PET ligands in the study of inhaled drug deposition. Aust J Chem. 2006;59(1):53–58.
   Web of Science ®Google Scholar
• Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299–303.
   PubMed Web of Science ®Google Scholar
• Constantino M, Waters SL, Steel CJ, et al. FlixotideTM-pressurized metered-dose inhalers loaded with [18F]fluticasone propionate particles for drug deposition studies in humans with PET–formulation and analysis. J Label Compd Radiopharm. 2004;47:55–70.
   Web of Science ®Google Scholar
• Bergström M, Nordberg A, Lunell E, et al. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther. 1995;57(3):309–317.
   PubMed Web of Science ®Google Scholar
• Lunell E, Bergström M, Antoni G, et al. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther. 1996;59(5):593–594.
   PubMed Web of Science ®Google Scholar
• Berridge MS, Apana SM, Nagano KK, et al. Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl). 2010;209(4): 383–394.
   PubMed Web of Science ®Google Scholar
• Apana SM, Berridge MS. Cigarettes labeled with [C-11]nicotine: formulation and administration for PET inhalation. J Labelled Compd Rad. 2010;53(1–2):6–10.
   Web of Science ®Google Scholar
• Rose JE, Mukhin AG, Lokitz SJ, et al. Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. Proc Natl Acad Sci U S A. 2010;107(11):5190–5195.
   PubMed Web of Science ®Google Scholar
• Solingapuram Sai KK, Zuo Y, Rose JE, et al. Rapid brain nicotine uptake from electronic cigarettes. J Nucl Med. 2020;61(6):928–930.
   PubMed Web of Science ®Google Scholar
• Wall A, Roslin S, Borg B, et al. E-cigarette aerosol deposition and disposition of [11C]nicotine using positron emission tomography: a comparison of nicotine uptake in lungs and brain using two different nicotine formulations. Pharmaceuticals. 2022;15(3).
   Web of Science ®Google Scholar
• Elsinga PH, van Waarde A, Vaalburg W. Receptor imaging in the thorax with PET. Eur J Pharmacol. 2004;499(1–2):1–13.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang ZY, Powers D, et al. Rolapitant absolute bioavailability and PET imaging studies in healthy adult volunteers. Clin Pharmacol Ther. 2017;102(2):332–339.
   PubMed Web of Science ®Google Scholar
• Raje S, Patat AA, Parks V, et al. A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer’s disease. Clin Pharmacol Ther. 2008;83(1):86–96.
   PubMed Web of Science ®Google Scholar
• Schou M, Ewing P, Cselenyi Z, et al. Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator. EJNMMI Res. 2019;9(1): 9.
   PubMedGoogle Scholar
• Maher TM, Simpson JK, Porter JC, et al. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled alphavbeta6 integrin inhibitor. Respir Res. 2020;21(1):75.
   PubMed Web of Science ®Google Scholar
• Hayes MJ, Qing F, Rhodes CG, et al. In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy. Am J Respir Crit Care Med. 1996;154(5):1277–1283.
   PubMed Web of Science ®Google Scholar
• van Waarde A, Maas B, Doze P, et al. Positron emission tomography studies of human airways using an inhaled beta-adrenoceptor antagonist, S-11C-CGP 12388. Chest. 2005;128(4): 3020–3027.
   PubMed Web of Science ®Google Scholar
• Cselenyi Z, Jucaite A, Kristensson C, et al. Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects. EJNMMI Res. 2020;10(1):59.
   PubMed Web of Science ®Google Scholar
• Tronde A, Nordén B, Marchner H, et al. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci. 2003;92(6):1216–1233.
   PubMed Web of Science ®Google Scholar
• Selo MA, Sake JA, Ehrhardt C, et al. Organic cation transporters in the lung-current and emerging (patho)physiological and pharmacological concepts. Int J Mol Sci. 2020;21(23):9168.
   PubMed Web of Science ®Google Scholar
• Nickel S, Clerkin CG, Selo MA, et al. Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opin Drug Deliv. 2016;13(5): 667–690.
   PubMed Web of Science ®Google Scholar
• Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A, et al. Spatial expression and functionality of drug transporters in the intact lung: objectives for further research. Adv Drug Deliv Rev. 2011;63(1–2):110–118.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Matsumaru T, Yamamura N, et al. Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J Pharm Sci. 2013;102(9):3395–3406.
   PubMed Web of Science ®Google Scholar
• Al-Jayyoussi G, Price DF, Kreitmeyr K, et al. Absorption of ipratropium and l-carnitine into the pulmonary circulation of the ex-vivo rat lung is driven by passive processes rather than active uptake by OCT/OCTN transporters. Int J Pharm. 2015;496(2):834–841.
   PubMedGoogle Scholar
• Al-Jayyoussi G, Price DF, Francombe D, et al. Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: a study in ex vivo lung models using chemical inhibition and genetic knockout. J Pharm Sci. 2013;102(9):3382–3394.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, et al. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos. 2012;40(9):1825–1833.
   PubMed Web of Science ®Google Scholar
• Cossio U, Gomez-Vallejo V, Flores M, et al. Preclinical evaluation of aerosol administration systems using Positron Emission Tomography. Eur J Pharm Biopharm. 2018;130:59–65.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Zwier R, Junginger HE, et al. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005;61(3):214–218.
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Suarez CJ, Dintzis SM, et al. Respiratory System. In: Treuting PM, Dintzis SM, Montine KS, editors. Comparative anatomy and histology (Second edition). A mouse, rat, and human atlas. Academic Press; 2017. p. 147–162.
   Google Scholar
• Okamura T, Kikuchi T, Okada M, et al. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J Cereb Blood Flow Metab. 2009;29(3):504–511.
   PubMed Web of Science ®Google Scholar
• Okamura T, Kikuchi T, Okada M, et al. Imaging of activity of multidrug resistance-associated protein 1 in the lungs. Am J Respir Cell Mol Biol. 2013;49(3):335–340.
   PubMed Web of Science ®Google Scholar
• Zoufal V, Mairinger S, Krohn M, et al. Influence of multidrug resistance-associated proteins on the excretion of the ABCC1 imaging probe 6-bromo-7-[11C]methylpurine in mice. Mol Imaging Biol. 2019;21(2):306–316.
   PubMed Web of Science ®Google Scholar
• Mairinger S, Sake JA, Hernández Lozano I, et al. Assessing the activity of multidrug resistance-associated protein 1 at the lung epithelial barrier. J Nucl Med. 2020;61(11): 1650–1657.
   PubMed Web of Science ®Google Scholar
• Hernández-Lozano I, Mairinger S, Filip T, et al. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. J Control Release. 2022;342:44–52.
   PubMed Web of Science ®Google Scholar
• Wanek T, Mairinger S, Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood–brain barrier. J Labelled Comp Radiopharm. 2013;56(3–4):68–77.
   PubMed Web of Science ®Google Scholar
• Mairinger S, Hernandez-Lozano I, Filip T, et al. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats. J Control Release. 2022;349:109–117.
   PubMed Web of Science ®Google Scholar
• Ruparelia P, Cheow HK, Evans JW, et al. Pulmonary elimination rate of inhaled 99mTc-sestamibi radioaerosol is delayed in healthy cigarette smokers. Br J Clin Pharmacol. 2008;65(4):611–614.
   PubMed Web of Science ®Google Scholar
• Mohan HK, Routledge T, Cane P, et al. Does the clearance of inhaled 99mTc-sestamibi correlate with multidrug resistance protein 1 expression in the human lung? Radiology. 2016;280(3):924–930.
   PubMed Web of Science ®Google Scholar
• Mohan HK, Livieratos L, Peters AM. Lung clearance of inhaled aerosol of Tc-99m-methoxyisobutyl isonitrile: relationships with cigarette smoking, age and gender. Clin Physiol Funct I. 2019;39(4):236–239
   PubMed Web of Science ®Google Scholar
• Hendrikse NH, Franssen EJ, van der Graaf WT, et al. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77(3):353–358.
   PubMed Web of Science ®Google Scholar
• Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990;31(10):1646–1653.
   PubMed Web of Science ®Google Scholar
• Burt T, Roffel AF, Langer O, et al. Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: is it time to change the drug development process in order to increase productivity? Clin Transl Sci. 2022;15(6):1355–1379.
   PubMed Web of Science ®Google Scholar
• Moek KL, Giesen D, Kok IC, et al. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017;58(Suppl 2):83S–90S.
   PubMedGoogle Scholar
• Chen DL, Cheriyan J, Chilvers ER, et al. Quantification of lung PET images: challenges and opportunities. J Nucl Med. 2017;58(2):201–207.
   PubMed Web of Science ®Google Scholar
• Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin alphavbeta6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging. 2020;47(4):967–979.
   PubMed Web of Science ®Google Scholar
• Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–1539.
   PubMed Web of Science ®Google Scholar
• Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models [Review]. J Cereb Blood Flow Metab. 2001;21(6):635–652.
   PubMed Web of Science ®Google Scholar
• Grootjans W, Rietbergen DD, van Velden FH. Added value of respiratory gating in positron emission tomography for the clinical management of lung cancer patients. Semin Nucl Med. 2022 May; 25 S0001-2998(22)00037-X. 10.1053/j.semnuclmed.2022.04.006. Online ahead of print.
   Google Scholar
• Lee Z, Berridge MS. PET imaging-based evaluation of aerosol drugs and their delivery devices: nasal and pulmonary studies. IEEE Trans Med Imaging. 2002;21(10):1324–1331.
   PubMed Web of Science ®Google Scholar
• Pike VW. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30(8):431–440.
   PubMed Web of Science ®Google Scholar